Broad-spectrum antiviral developed by Gilead, used in IV treatment settings
Scientists at Oxford have begun Phase I trials of a ChAdOx BDBV vaccine for Bundibugyo Ebola in healthy UK adults, with 620,000 doses stockpiled and partnerships for African trials. The trial monitors safety and immune response for a year as the outbreak expands in the Democratic Republic of Congo.
A Senate hearing has spotlighted newly released diary pages from Fauci, fueling accusations that the scientist privately contradicted public statements as lawmakers push for questioning under the Fifth Amendment; experts note the diary entries document uncertainty in early pandemic days and ongoing debates about origins and gain-of-function research.
The Bundibugyo strain of Ebola has reached unprecedented speed, with cases surpassing 4,000 and deaths above 2,000. Health workers face strikes over pay, security risks rise amid conflict, and aid cuts hinder response as experts warn the outbreak could escalate further.